REGENERON PHARMACEUTICALS, INC. Equity Securities, FV-NI, Realized Gain (Loss)
REGENERON PHARMACEUTICALS, INC. (REGN) reported Equity Securities, FV-NI, Realized Gain (Loss) of $966.20 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-04.
Financial Statements › Income Statement › Other Income
us-gaap:EquitySecuritiesFvNiRealizedGainLoss · last filed 2026-02-04
- REGENERON PHARMACEUTICALS, INC. equity securities, fv-ni, realized gain (loss) for the quarter ending 2025-12-31 was $315.80M.
- REGENERON PHARMACEUTICALS, INC. equity securities, fv-ni, realized gain (loss) for the quarter ending 2025-09-30 was $370.90M.
- REGENERON PHARMACEUTICALS, INC. equity securities, fv-ni, realized gain (loss) for the quarter ending 2024-12-31 was $0.00.
- REGENERON PHARMACEUTICALS, INC. equity securities, fv-ni, realized gain (loss) for the quarter ending 2024-09-30 was $0.00.
- REGENERON PHARMACEUTICALS, INC. equity securities, fv-ni, realized gain (loss) for fiscal 2025 was $966.20M.
- REGENERON PHARMACEUTICALS, INC. equity securities, fv-ni, realized gain (loss) for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- REGENERON PHARMACEUTICALS, INC. equity securities, fv-ni, realized gain (loss) for fiscal 2023 was $6.00M.
| Period end | Equity Securities, FV-NI, Realized Gain (Loss) 3 month | Equity Securities, FV-NI, Realized Gain (Loss) 6 month | Equity Securities, FV-NI, Realized Gain (Loss) 9 month | Equity Securities, FV-NI, Realized Gain (Loss) 12 month |
|---|---|---|---|---|
| 2025-12-31 | $315.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-04 | $686.70M derived: sum of 2 quarters · filed 2026-02-04 | $966.20M 10-K · filed 2026-02-04 | |
| 2025-09-30 | $370.90M 10-Q · filed 2025-10-28 | $650.40M 10-Q · filed 2025-10-28 | ||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-04 | $0.00 derived: sum of 2 quarters · filed 2026-02-04 | $0.00 10-K · filed 2026-02-04 | |
| 2024-09-30 | $0.00 10-Q · filed 2025-10-28 | $0.00 10-Q · filed 2025-10-28 | ||
| 2023-12-31 | $6.00M 10-K · filed 2026-02-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 |